<?xml version="1.0" encoding="UTF-8"?>
<p>Hepatitis C virus (HCV) infection is a major cause of liver-related complications and mortality in human immunodeficiency virus (HIV)-infected populations in high-income settings [
 <xref rid="OFW049C1" ref-type="bibr">1</xref>]. However, its importance seems to vary widely across the African continent. Although the prevalence of anti-HCV antibody-positivity lies between 4% and 7% in most of sub-Saharan Africa (SSA) [
 <xref rid="OFW049C2" ref-type="bibr">2</xref>], there are large differences in the reported prevalence of replicating (ribonucleic acid [RNA]-positive) HCV infections, which ranges from &lt;1% in southern Africa to &gt;10% in Central Africa [
 <xref rid="OFW049C3" ref-type="bibr">3</xref>â€“
 <xref rid="OFW049C5" ref-type="bibr">5</xref>]. Only a few studies have confirmed their HCV screening findings with RNA testing.
</p>
